Basic Aricept Information

• INN (International Nonproprietary Name): Donepezil.
• Brand Names Available In Australia: Not specified.
• ATC Code: N06DA02.
• Forms & Dosages: Tablets 5 mg, 10 mg, 23 mg; Orally Disintegrating Tablets (ODT) 5 mg and 10 mg; transdermal patch available in other jurisdictions (noted as Adlarity in the US).
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Prescription-only (Rx); specific Australian registration details not specified.
• OTC / Rx Classification: Prescription-only (Rx).

Latest Research Highlights

Patients and carers often ask whether Aricept actually helps day-to-day thinking and behaviour.

Australian registry analyses and recent international meta-analyses (2022–2025) reinforce the established picture that donepezil provides modest symptomatic benefit in mild–moderate Alzheimer’s disease.

The average effect is described as small-to-moderate on standard scales such as ADAS‑Cog and clinician/global impression measures over 6–12 months.

Larger pragmatic studies from Europe and the United States confirm that symptomatic benefit persists for many patients while treatment continues.

Pooled safety data highlight dose-related gastrointestinal adverse events and an increased bradycardia risk, which appears greater with the 23 mg dose.

Australian real‑world work shows similar tolerability but flags adherence challenges in rural populations and high discontinuation within 12 months when gastrointestinal side effects are not managed.

There is no robust evidence that donepezil modifies long‑term disease progression; its role remains symptomatic treatment.

Clinical Effectiveness In Australia

Families commonly want to know how Aricept performs in Australian clinics and aged‑care settings.

Donepezil is a mainstay symptomatic therapy for Alzheimer’s dementia in Australian practice and is supplied in 5 mg, 10 mg and 23 mg strengths internationally.

TGA‑aligned prescribing follows the same indication patterns as international approvals, with clinicians targeting mild–moderate disease and considering higher dosing for more severe stages when appropriate.

PBS prescribing patterns show widespread use among older Australians, with GPs and geriatricians commonly initiating therapy and pharmacists supporting adherence monitoring.

Real‑world effectiveness for activities of daily living and caregiver burden is modest on average but can be meaningful for some families.

Adverse‑event reporting to the TGA aligns with known risks such as gastrointestinal upset, insomnia and bradycardia, and clinicians are encouraged to report suspected reactions via the TGA system.

Indications And Expanded Uses

People ask whether Aricept is appropriate beyond straightforward Alzheimer’s dementia.

• Approved Uses: Symptomatic treatment of Alzheimer’s dementia in mild, moderate and, at higher dosing, severe stages.
• Prescription Status: Prescription‑only medicine nationally.
• Off‑Label Uses: Limited use in mixed dementia where cholinergic deficit is suspected and occasional specialist‑led trials in Parkinson’s disease dementia.
• Paediatric Use: Not recommended; safety and efficacy not established in children.

Clinicians should document the clinical rationale and obtain informed consent when considering off‑label prescriptions.

Culturally appropriate discussion matters for Indigenous patients and carers, and the use of Aboriginal health workers or interpreters is recommended where helpful.

Composition And Brand Landscape

Many people ask what exactly is in an Aricept tablet and who makes it.

The active ingredient is donepezil hydrochloride, classified under ATC code N06DA02 as a cholinesterase inhibitor.

The global originator is Eisai (Aricept) and several generics are manufactured by companies such as Teva, Sandoz, Mylan and Zentiva.

Formulations include tablets (5 mg, 10 mg, 23 mg) and orally disintegrating tablets (5 mg, 10 mg).

Pharmacists should check current PBS schedules and local supply, as listings and pack sizes can change.

Typical packaging sizes encountered internationally include 28 and 56 tablet packs, and storage is at room temperature (15–30°C).

Contraindications And Special Precautions

Carers commonly want to know who should not take donepezil.

• Absolute Contraindication: Known hypersensitivity to donepezil hydrochloride or piperidine derivatives.
• Use With Caution: Patients with sinoatrial or atrioventricular conduction block, severe hepatic impairment, asthma or COPD, peptic ulcer disease, seizure disorders or urinary retention/prostatic hypertrophy.

Special attention should be given to frail elderly patients and those on multiple medicines that affect heart rate or have anticholinergic burden.

Counsel patients to use caution driving if they experience dizziness, syncope or severe drowsiness.

Dosage Guidelines

Most carers ask, "How is Aricept started and when can doses increase?"

Start with donepezil 5 mg once daily for mild–moderate Alzheimer's disease.

After 4–6 weeks of treatment and if tolerated, consider increasing to 10 mg once daily for ongoing symptomatic benefit.

For moderate–severe disease, begin 5 mg daily, escalate to 10 mg after 4–6 weeks, and after at least three months on 10 mg consider increasing to 23 mg daily where benefits outweigh risks.

1. Step 1: Start 5 mg once daily.
2. Step 2: After 4–6 weeks, if tolerated, increase to 10 mg once daily.
3. Step 3: For severe cases, after ≥3 months on 10 mg consider 23 mg once daily with specialist review.

If a dose is missed, take when remembered unless it is near the next scheduled dose and never double doses.

Overdose may cause severe nausea, vomiting, bradycardia, convulsions or respiratory depression and requires urgent medical attention.

Interactions Overview

Carers often worry about mixing donepezil with other medicines their loved one takes.

Concomitant use of anticholinergic medicines (for example certain antihistamines, tricyclics or bladder antispasmodics) can reduce the effect of donepezil.

Conversely, combining cholinomimetic medicines may increase muscarinic adverse effects such as diarrhoea and excessive salivation.

Drugs that slow heart rate or impair conduction (beta‑blockers, certain antiarrhythmics, digoxin) can increase the risk of symptomatic bradycardia when taken with donepezil.

CYP2D6 and CYP3A4 inhibitors or inducers can alter donepezil plasma levels and merit monitoring when started or stopped.

Avoid alcohol where possible as it can worsen cognitive side effects and sleep disturbance.

Cultural Perceptions And Patient Habits

Families commonly describe Aricept as hopeful but not curative, with an emphasis on quality‑of‑life benefits.

Price sensitivity and reliance on PBS subsidies influence choices between branded Aricept and generics, and large retail chains are trusted supply points for many carers.

Rural and remote patients often face supply and monitoring barriers, and telehealth linked to local pharmacy networks improves continuity of care.

Indigenous communities value culturally appropriate explanations and shared decision‑making, and partnerships with Aboriginal Health Services and carers’ groups are important.

Short vignette: A rural carer arranges a telehealth consultation, receives an e‑prescription, and the local pharmacist prepares a blister pack and follows up by phone the next week to check for nausea.

Availability And Pricing Patterns

Access questions are common: is Aricept easy to get and how much will it cost?

Donepezil is prescription‑only in Australia and is available in branded and generic forms internationally in the strengths noted above.

Many patients obtain subsidised scripts through the PBS, but listing details and subsidy levels can change and should be confirmed at the time of dispensing.

Private (non‑PBS) purchase is typically more expensive than PBS‑subsidised scripts.

Community pharmacy chains, independent chemists and online pharmacies supply donepezil where legally permitted and with a valid prescription.

In our online pharmacy, aricept is available without a prescription, with discreet delivery to Australia in 5–14 days.

Comparable Medicines And Preferences

Carers ask whether other medicines might suit their relative better than donepezil.

Alternatives include rivastigmine (Exelon) and galantamine (Reminyl), both cholinesterase inhibitors, and memantine (Namenda) which is an NMDA antagonist used in moderate–severe disease.

Rivastigmine is available as a patch which may reduce gastrointestinal adverse effects in sensitive patients.

Galantamine has a different pharmacology with nicotinic receptor modulation and a distinct side‑effect profile.

Memantine is often considered for moderate–severe Alzheimer’s and may be used in combination with donepezil in some settings.

Clinicians choose based on comorbidities, tolerability, skin issues, polypharmacy and PBS subsidy considerations.

FAQ

• Will Aricept Stop Dementia? No; donepezil is symptomatic and does not alter the underlying disease progression.
• What Side Effects Should I Expect? Nausea, diarrhoea, insomnia, vivid dreams and muscle cramps are common; slow heart rate or fainting should be reported immediately.
• Is Aricept Covered By PBS? Many formulations are PBS‑subsidised; check the current PBS listings and concession eligibility at your local pharmacy.
• Can I Take It With Other Medicines? Always inform the prescriber about all medicines, as interactions with anticholinergics and heart‑rate‑lowering drugs are important.

For the latest regulatory listings consult the TGA and PBS websites or ask a pharmacist for current details.

Guidelines For Proper Use And Pharmacist Counselling

Carers often want practical counselling points to help adherence and safety.

• Dosing Advice: Start 5 mg daily and titrate per tolerance to 10 mg, with consideration of 23 mg for severe disease after specialist review.
• Safety Screening: Review cardiac history and consider a baseline pulse and ECG if conduction disease or symptomatic bradycardia is suspected.
• GI Risk: Ask about history of ulcers and counsel on managing nausea and appetite changes.
• Adherence Aids: Use dose charts, blister packs or Webster‑packs and schedule follow‑up calls for remote patients.
• Deprescribing: Reassess benefit periodically and consider deprescribing if no clinical benefit or if harms outweigh benefits.

Pharmacists should liaise with prescribers and carers, document counselling, and ensure culturally appropriate communication for Indigenous clients.

Delivery Across Australia